Lunai Bioworks (LNAI) Asset Writedowns and Impairment (2023 - 2025)
Lunai Bioworks (LNAI) posted quarterly Asset Writedowns and Impairment of $122.8 million for Q2 2025, up 157.91% quarter-over-quarter from $47.6 million in Q3 2024.
Lunai Bioworks (LNAI) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Lunai Bioworks' Asset Writedowns and Impairment history runs 3 years deep, the most recent figure standing at $122.8 million for Q2 2025.
- In Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $122.8 million; the TTM figure through Jun 2025 stood at $122.8 million (up 99.45% YoY), while the FY2025 annual figure was $122.8 million, up 188.2% from the prior year.
- Asset Writedowns and Impairment for Q2 2025 stood at $122.8 million, up from $47.6 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $122.8 million in Q2 2025, with the low at $19.0 million in Q2 2023.
- The 3-year median for Asset Writedowns and Impairment is $45.1 million (2024), against an average of $58.0 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 122.80 Mn |
| Jun 30, 2025 | 122.80 Mn |
| Sep 30, 2024 | 47.61 Mn |
| Sep 30, 2024 | 47.61 Mn |
| Mar 31, 2024 | 42.61 Mn |
| Mar 31, 2024 | 42.61 Mn |
| Jun 30, 2023 | 18.96 Mn |
| Jun 30, 2023 | 18.96 Mn |